ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Cardiovascular Epidemiology and Prevention
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1564785
This article is part of the Research TopicImpact of Environmental Factors on Healthy Aging: Behavioral Pathways and Health OutcomesView all 17 articles
The Disproportionate Burden of Pulmonary Arterial Hypertension A mong the Elderly: Global, Regional, and National Trends from 1990 to 2021 -Findings from the 2021 Global Burden of Disease Stud
Provisionally accepted- 1Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China
- 2Guanganmen Hospital, Affiliated to China Academy of Chinese Medical Sciences, Beijing, China
- 3Bao'an Authentic TCM Therapy Hospital, Shenzhen City, Guangdong Province, China
- 4Jiangxi Province Hospital of Integrated Chinese and Western Medicine, Nanchang, Jiangxi Province, China
- 5The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: Pulmonary arterial hypertension (PAH) is a chronic vascular disorder characterized by elevated pulmonary artery pressure and pulmonary vascular resistance, leading to right ventricular failure. This condition imposes a substantial economic burden and significant health challenges globally. This study aimed to comprehensively analyze the global burden of PAH, with specific attention to vulnerable populations including the elderly, by evaluating gender, age (especially older age groups), region, country, and sociodemographic variables using data from the Global Burden of Disease Study (GBD) 2021.Methods: Utilizing GBD 2021 data, we assessed the global, regional, and national burden and trends of PAH through metrics like age-standardized prevalence, mortality, and disability-adjusted life years (DALYs). Analyses included decomposition, health inequality, and frontier analysis.Age-period-cohort (APC) modeling was used to examine period and cohort effects (1990-2021), and future burden was projected using Bayesian APC (BAPC) modeling.In 2021, while PAH prevalence and mortality counts were higher than previous years, age-standardized rates (prevalence -ASPR, mortality -ASMR/ASDR) and DALYs showed a declining trend. Crucially, the disease burden was significantly higher among females and, notably, the elderly population compared to males and younger age groups. Low Socio-Demographic Index (SDI) regions consistently bore a disproportionately higher burden of mortality and DALYs.Decomposition analysis identified population growth and population aging as major drivers of the overall PAH burden. Age-period-cohort effects confirmed that disease risk increased substantially with advancing age. BAPC projections suggest a potential decrease in the global PAH burden by 2035.Conclusions: Progress in reducing the PAH disease burden during 1990-2021 was limited globally, nationally, and regionally. This lack of progress was particularly pronounced among women and, critically, older age groups. Diagnosis, treatment, and prevention strategies remain critically insufficient in low-and middle-income countries. Therefore, proactively developing health policies tailored to the PAH disease burden -with specific consideration for the growing elderly population and aligned with national/regional economic development -is essential to address this major public health challenge.
Keywords: pulmonary arterial hypertension, Prevalence, Mortality, Disability-adjusted life years, Epidemiology, Global burden of disease, Elderly, Aging
Received: 23 Jan 2025; Accepted: 24 Jun 2025.
Copyright: © 2025 Tang, Liu, Hao, Liu, Li, Luo and Zou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Meng Tang, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China
Guohui Zou, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.